Analysts expect Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to report earnings of ($1.39) per share for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Adamas Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.19) and the lowest estimate coming in at ($1.58). Adamas Pharmaceuticals posted earnings per share of ($1.27) in the same quarter last year, which indicates a negative year over year growth rate of 9.4%. The company is scheduled to issue its next earnings report on Thursday, February 28th.
According to Zacks, analysts expect that Adamas Pharmaceuticals will report full-year earnings of ($5.23) per share for the current fiscal year, with EPS estimates ranging from ($5.52) to ($5.01). For the next fiscal year, analysts anticipate that the business will report earnings of ($3.87) per share, with EPS estimates ranging from ($4.31) to ($2.89). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Adamas Pharmaceuticals.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings data on Thursday, November 1st. The specialty pharmaceutical company reported ($1.22) EPS for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.12. The business had revenue of $10.61 million for the quarter, compared to analyst estimates of $10.10 million. Adamas Pharmaceuticals had a negative return on equity of 106.74% and a negative net margin of 617.27%.
ADMS opened at $10.51 on Friday. The company has a current ratio of 8.95, a quick ratio of 8.74 and a debt-to-equity ratio of 1.01. The firm has a market cap of $270.08 million, a P/E ratio of -2.65 and a beta of 1.53. Adamas Pharmaceuticals has a 52 week low of $9.69 and a 52 week high of $44.00.
In other Adamas Pharmaceuticals news, CEO Gregory T. Went purchased 3,850 shares of the firm’s stock in a transaction on Wednesday, November 7th. The shares were purchased at an average cost of $12.98 per share, with a total value of $49,973.00. Following the purchase, the chief executive officer now owns 182,610 shares in the company, valued at $2,370,277.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alfred G. Merriweather sold 1,665 shares of the firm’s stock in a transaction dated Friday, September 21st. The stock was sold at an average price of $19.18, for a total value of $31,934.70. Following the completion of the sale, the chief financial officer now directly owns 25,460 shares in the company, valued at $488,322.80. The disclosure for this sale can be found here. 24.60% of the stock is currently owned by company insiders.
A number of large investors have recently modified their holdings of the business. California State Teachers Retirement System raised its holdings in shares of Adamas Pharmaceuticals by 11.2% in the 1st quarter. California State Teachers Retirement System now owns 26,179 shares of the specialty pharmaceutical company’s stock worth $626,000 after purchasing an additional 2,645 shares during the period. Allianz Asset Management GmbH raised its holdings in shares of Adamas Pharmaceuticals by 4.7% in the 1st quarter. Allianz Asset Management GmbH now owns 55,594 shares of the specialty pharmaceutical company’s stock worth $1,329,000 after purchasing an additional 2,513 shares during the period. Emerald Advisers Inc. PA raised its holdings in shares of Adamas Pharmaceuticals by 2.2% in the 2nd quarter. Emerald Advisers Inc. PA now owns 639,934 shares of the specialty pharmaceutical company’s stock worth $16,529,000 after purchasing an additional 13,821 shares during the period. Emerald Mutual Fund Advisers Trust raised its holdings in shares of Adamas Pharmaceuticals by 3.4% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 550,354 shares of the specialty pharmaceutical company’s stock worth $14,216,000 after purchasing an additional 17,877 shares during the period. Finally, Kornitzer Capital Management Inc. KS raised its holdings in shares of Adamas Pharmaceuticals by 81.9% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 318,890 shares of the specialty pharmaceutical company’s stock worth $8,237,000 after purchasing an additional 143,535 shares during the period. 91.84% of the stock is currently owned by hedge funds and other institutional investors.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Featured Article: How can you know how many shares are floating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.